Presage Biosciences

Executive Summary

Presage Biosciences is a preclinical-stage oncology company pioneering a novel approach to intratumoral drug evaluation via its patented CIVO (Comparative In Vivo Oncology) platform. The CIVO technology enables direct microinjection of multiple investigational drugs or combinations into a patient's tumor, allowing real-time assessment of tumor microenvironment responses. This approach aims to accelerate drug development by providing early, clinically relevant efficacy data without systemic exposure. Founded in 2007 and based in Seattle, the company operates in the drug delivery and oncology sectors, targeting a key bottleneck in oncology R&D—the low success rate of preclinical candidates moving to clinical approval. Although still in preclinical stages, Presage's platform has the potential to transform how drug developers select lead candidates, design combination therapies, and reduce costly late-stage failures. The company's current focus is on advancing its platform through strategic partnerships with pharmaceutical firms seeking to de-risk their oncology pipelines.

Upcoming Catalysts (preview)

• Q3 2026Strategic Licensing or Partnership Deal with a Top Pharma45% success
• Q4 2026First-in-Human Clinical Trial Application Submission30% success
• Q1 2027Series B or Later-Stage Funding Round Announcement60% success